Elisabetta Fenu
Royal College of Physicians
13 Papers
40 Citations
Elisabetta Fenu is an academic researcher from Royal College of Physicians. The author has contributed to research in topics: Cost effectiveness & Medicine. The author has an hindex of 6, co-authored 10 publications.
Chat about Author
Papers
Clinical assessment and management of multimorbidity: summary of NICE guidance
TL;DR: This guideline is intended to provide guidance on the optimum management of people with multimorbidity who need an approach to care which is largely based on trials of interventions for single conditions, from which people with multi-million dollar conditions are often excluded.
226
Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance
TL;DR: This article summarises the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the management of confirmed or suspected venous thromboembolic diseases in adults (excluding pregnant women).
74
Management of stable angina: summary of NICE guidance
TL;DR: This article summarises the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the management of stable angina.
50
National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical Excellence.
TL;DR: How cost-effectiveness is evaluated and accounted for in NCGC guidelines is described, as well as some of the challenges faced in trying to account for cost-Effectiveness in clinical guidelines.
41
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
Elisabetta Fenu,Vasily Lukyanov,Annabel Acs,X. Radu,Stephanie A. Stypa,R. Fischer,John C. Marshall,Mark Oppe +7 more
- 26 Apr 2022
TL;DR: In this article , a hybrid decision tree/Markov model was developed to evaluate vedolizumab SC costs, quality-adjusted life-years, and cost effectiveness vs conventional and advanced therapeutics in patients with moderately to severely active ulcerative colitis from a Canadian public healthcare payer perspective.